Company intelligence / Profile preview

Evariste

Goring/Reading/Oxford*, England, United Kingdomevariste.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Evariste uses its proprietary Frobenius AI platform to identify novel synthetic lethal targets in oncology and design differentiated small molecule therapeutics. The company reports achieving best-in-class potency/selectivity in fewer than 50 compounds per program, with a roughly tenfold potency increase for every 30 compounds tested. Programs are at the preclinical/early validation stage.[1][2] No clinical results have been published.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Collaborative projects referenced but none named

Beyond the preview

Go deeper on Evariste.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evariste.

Explore the full profile